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Abstract
Pancreatic cancer has a 5-year survival rate of less than 4%. Despite advances in diagnos-
tic technology, pancreatic cancer continues to be diagnosed at a late and incurable stage.
Accurate biomarkers for early diagnosis and to predict treatment response are urgently
needed. Since alteration of glucose metabolism is one of the hallmarks of cancer cells, we
proposed that pyruvate kinase type M2 (M2PK) and lactate dehydrogenase A (LDHA)
enzymes could represent novel diagnostic markers and potential therapeutic targets in pan-
creatic cancer. In 266 tissue sections from normal pancreas, pancreatic cystic neoplasms,
pancreatic intraepithelial neoplasia (PanIN) and cancer, we evaluated the expression of
PKM2, LDHA, Ki-67 and CD8+ by immunohistochemistry and correlated these markers
with clinicopathological characteristics and patient survival. PKM2 and LDHA expression
was also assessed by Western blot in 10 human pancreatic cancer cell lines. PKM2 expres-
sion increased progressively from cyst through PanIN to cancer, whereas LDHA was over-
expressed throughout the carcinogenic process. All but one cell line showed high
expression of both proteins. Patients with strong PKM2 and LDHA expression had signifi-
cantly worse survival than those with weak PKM2 and/or LDHA expression (7.0 months vs.
27.9 months, respectively, p = 0.003, log rank test). The expression of both PKM2 and
LDHA correlated directly with Ki-67 expression, and inversely with intratumoral CD8+ cell
count. PKM2 was significantly overexpressed in poorly differentiated tumours and both
PKM2 and LDHA were overexpressed in larger tumours. Multivariable analysis showed that
combined expression of PKM2 and LDHA was an independent poor prognostic marker for
survival. In conclusion, our results demonstrate a high expression pattern of two major gly-
colytic enzymes during pancreatic carcinogenesis, with increased expression in aggressive
tumours and a significant adverse effect on survival.
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Introduction
Pancreatic cancer is one of the most common gastrointestinal cancers and the fourth most
common cause of cancer-related deaths worldwide [1]. Surgical resection is the most effective
therapy but patients are usually diagnosed at an advanced stage when surgical resection is not
feasible, resulting in a five year survival rate of less than 4% [2]. There are few other effective
therapies, with palliative single-agent or combination chemotherapy as the main treatment
option for patients with advanced disease [3,4].
Aerobic glycolysis is a hallmark of cancer cells, with the production of lactate even in the
presence of ample amounts of oxygen, a phenomenon known as the Warburg effect [5–7]. An
important advantage of increased glycolysis in tumour cells is production of energy without
the consumption of oxygen and glycolytic intermediates, such as amino acids, nucleotides,
phospholipids and triglycerides, which are used as macromolecules for the synthesis of struc-
tural elements of new cells [5,6,8,9].
Pyruvate kinase (PK) is a tightly regulated glycolytic enzyme that catalyses the last step of
glycolysis and mediates the transfer of phosphate from phosphoenolpyruvate (PEP) to adeno-
sine diphosphate (ADP) to produce pyruvate and energy (ATP) [10–12]. PK has four different
isoenzymes PKM1, PKM2, PKL and PKR, the expression of which depends on the metabolic
response of cells. Both L and M genes encode PK isoenzymes. The L gene encodes both L and
R-PK isoenzymes, while the M gene encodes both M1 and M2 isoenzymes (PKM2) [13–17].
During tumorigenesis, the expression of specific PK isoenzymes, for instance PK-M1 in the
brain and PK-L in the liver, disappears and PKM2 expression predominates [18]. PKM2
expression can oscillate between the highly active tetrameric isoform and the nearly inactive
dimeric isoform, depending on the cellular demand of energy or production of anabolic inter-
mediates for cell proliferation. The tetrameric isoform of PKM2 is predominantly expressed in
normal cells, while its dimeric isoform is usually found in tumour cells, hence the name tumour
PKM2 [11,14,19].
Another downstream component in the glycolytic pathway is the lactate dehydrogenase A
(LDHA) enzyme, which is a part of the LDH family of 2-hydroxyacid oxidoreductases. LDHs
are homo- and hetero- tetrameric enzymes comprised of two major subunits, A and B, result-
ing in five isoenzymes that catalyse the reversible conversion of pyruvate and lactate. LDHA
(also known as LDH-5, LDH-M or A4) is encoded by the ldh-a gene and predominates in skel-
etal muscle and liver, while LDHB (also known as LDH-1, LDH-H or B4) is encoded by the
ldh-b gene and is found mainly in the heart and brain [20–24]. LDH-C is mainly composed of
X-subunits and is found in human spermatozoa [22,25]. LDHA catalyses the conversion of
pyruvate into lactate with regeneration of NAD+ to continue energy production by glycolysis
[26–29]. Lactate produced by LDHA is used as an alternative fuel by cells that are adjacent to
blood vessels, and glucose is spared for more distant cells that are hypoxic.
Overexpression of PKM2 or LDHA has been reported in the tissues of a number of cancers,
including cholangiocarcinoma, colorectal cancer, non-small cell lung cancer and pancreatic
cancer. Overexpression is associated with tumour initiation, progression and resistance to che-
motherapy [27,30–32]. In theory, the expression profile of these enzymes may also represent
useful diagnostic or prognostic markers in pancreatic cancer [15,23,33].
CD8+ T cells (Cytotoxic T lymphocytes) are an important subset of tumour infiltrating lym-
phocytes that play a key role in the anti-tumour immune response. Immunohistochemistry
studies have shown an anti-tumour effect of infiltrating CD8+ lymphocytes, with improved
survival rates of patients with pancreatic, lung, ovarian, colorectal, renal and oesophageal
tumours [34–39], and a direct correlation between increasing number of CD8+ tumour infil-
trating lymphocytes (TILs) and tumour cell apoptosis [40,41].
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The aim of our study was to evaluate the expression of PKM2 and LDHA in pancreatic pre-
neoplastic lesions (cysts and pancreatic intraepithelial neoplasia, PanIN) and cancers and to
correlate it with patient outcome. Given that PKM2 and LDHA are involved in several cell pro-
liferation signaling pathways [42], we also investigated whether the expression of these glyco-
lytic enzymes correlated with the number of CD8+TILs and markers of tumour proliferation
(Ki-67).
Materials and Methods
Patients
This study included pancreatic biopsy or surgical resection specimens from 266 patients; 136
from University College London Hospital NHS Foundation Trust (UCLH) and another 130
from a commercially available tissue microarray (TMAs) (AccuMaxArray, ISU ABXIS CO.,
LTD, USA, and Insight Biotechnology Limited, UK). The UCLH cohort consisted of 136
patients with confirmed pancreatic ductal adenocarcinoma (PDAC) (n = 61), ampullary ade-
nocarcinoma (n = 11), pancreatic cystic lesions (n = 49), chronic pancreatitis (n = 11) and nor-
mal pancreatic tissue (n = 4). These patients had been treated at UCLH between January 2005
and January 2010. A clinical database of the UCLH patients was created through the CoPath
histology database, which included the following clinicopathological parameters: gender, age at
diagnosis, sample type (biopsy or resection), type of tumour (ampullary or ductal), outcome
(alive or dead), cause of death, length of follow-up if alive, presence or absence of metastatic
disease at the time of histological diagnosis, whether resection was carried out, residual disease
(R) status, post-resection recurrence, time to post-resection recurrence (if any), cancer stage,
lymph node involvement, presence of perineural or lymphovascular invasion, degree of tumour
differentiation, and whether patients received chemotherapy (Table 1). All data were collected
from the date of histological diagnosis to the date of death or the end of data collection on 1
February 2015. Ethics committee approval was obtained from the Central London REC 3
Research Ethics Committee to perform immunohistochemistry on stored biopsy and resection
specimens linked with a clinical database with the need for consent waived (REC reference 06/
Q0512/106, amendment date 30 July 2010). All patient samples were anonymised and de-iden-
tified prior to analysis.
Tissue microarray
A second validation set of 130 tissue samples was derived from commercially available pancre-
atic TMAs. A total of 206 tissue cores from 130 patients (83 male, 47 female, median age 59,
range 32–80 years) were present on the TMAs, which included 63 cases of PDAC in duplicate,
19 PanIN (10 PanIN-1, 7 PanIN-2 and 2 PanIN-3), 10 chronic pancreatitis and 38 normal pan-
creatic tissue cores. Histological diagnosis of all cases was verified by haematoxylin and eosin
staining. Clinical data provided with the TMAs included tumour size and stage, degree of
tumour differentiation, lymph node involvement, metastatic status and tumour sites.
Immunohistochemistry
Standard immunohistochemistry methods were used to detect the expression of PKM2,
LDHA, CD8 and Ki-67. Briefly, paraffin embedded sections were pre-heated in an oven for 30
minutes at 60°C, and then deparaffinised in xylene and hydrated through a series of graded eth-
anol (70%-95%). The sections were subjected to heat-mediated antigen retrieval with citrate
buffer (pH 4.0) in an autoclave. Endogenous peroxidase activity was inhibited by 3% hydrogen
peroxide for 20 minutes, followed by incubation with 2.5% normal horse blocking serum for 20
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minutes. The sections were then incubated with primary antibody for one hour at room tem-
perature for CD8 (CD8A Rabbit polyclonal antibody, Abnova, UK, Cat# PAB11235, 1:200)
Table 1. Correlation of PKM2 and LDHA expression with clinicopathological factors (UCLH cohort).
Variables Total
(n = 72)
PKM2 Expression P
value
LDH-A Expression P
value
Combined expression P
value
Positive Negative Positive Negative Positive* Negative**
(High) (Low) (High) (Low) (High) (Low)
(n = 46) (n = 26) (n = 55) (n = 17) (n = 44) (n = 28)
n (%) n (%) n (%) n (%) n (%) n (%)
Tumour Types
PDAC 61 41 (89) 20 (77) 0.171 48 (87) 13 (76.5) 0.249 40 (91) 21 (75) 0.088
Ampullary 11 5 (11) 6 (23) 7 (13) 4 (23.5) 4 (9) 7 (25)
Sex
Male 39 25 (54.4) 14 (53.8) 0.968 29 (52.7) 10 (58.8) 0.46 21 (47.7) 18 (64.3) 0.116
Female 33 21 (45.6) 12 (46.2) 26 (47.3) 7 (41.2) 23 (52.3) 10 (35.7)
Age at Diagnosis (years)
Mean ± SD 72 63.2
±11.9
65±9.4 0.502 63.8
±11.1
64±11.6 0.959 62.7±11.4 65.6±10.4 0.339
Tumour Differentiation
Well/Mod 18 8 (32.5) 10 (77.5) 0.047 13 (26) 5 (74) 0.63 8 (18.2) 10 (35.7) 0.094
Mod/Poor 54 38 (67.5) 16 (32.5) 42 (74) 12 (26) 36 (81.8) 18 (64.3)
Metastasis Status
Patients with metastasis 20 15 (32.6) 5 (19.3) 0.229 15 (27.3) 5 (29.4) 0.942 15 (34.1) 5 (17.8) 0.104
Patients without metastasis 52 31 (67.4) 21 (80.7) 40 (72.7) 12 (70.6) 29 (65.9) 23 (82.2)
Lymph Node Involvement
Positive lymph node 16 10 (21.7) 6 (23) 0.504 13 (23.6) 3 (17.6) 0.942 9 (20.5) 7 (25) 0.444
Negative lymph node 11 6 (13) 5 (19.3) 8 (14.5) 3 (17.6) 5 (11.4) 6 (21.4)
Unknown 45 30 (65.3) 15 (57.7) 34 (61.9) 11 (64.7) 30 (68.1) 15 (53.6)
Clinical T-Stage
Classiﬁcation
T1 0 0 (0) 0 (0) 0.615 0 (0) 0 (0) 0.402 0 (0) 0 (0) 0.358
T2 7 3 (6.5) 4 (15.4) 4 (7.3) 3 (17.6) 3 (6.9) 4 (14.3)
T3 11 7 (15.2) 4 (15.4) 10 (18.2) 1 (5.9) 7 (15.9) 4 (14.3)
T4 9 6 (13) 3 (10.7) 7 (12.7) 2 (11.8) 4 (9.1) 5 (17.8)
Unknown 45 30 (62.3) 15 (53.5) 34 (61.8) 11 (64.7) 30 (68.1) 15 (53.6)
Staging
Stage I 3 1 (2.2) 2 (7.7) 0.503 1 (1.8) 2 (11.8) 0.2 2 (4.6) 1 (3.5) 0.264
Stage II 13 7 (15.2) 6 (23) 11 (20) 2 (11.8) 6 (13.6) 7 (25)
Stage III 9 6 (13) 3 (11.5) 7 (12.7) 2 (11.8) 4 (9.1) 5 (17.9)
Stage IV 2 2 (4.4) 0 (0) 2 (3.6) 0 (0) 2 (4.6) 0 (0.0)
Unknown 45 30 (65.2) 15 (57.8) 34 (61.9) 11 (64.6) 30 (68.1) 15 (53.6)
Mean of CD8/HPF
Mean ± SD 72 16.3
±24.3
42.4
±43.1
0.0001 20.1
±30.7
44.3
±40.1
0.005 16.4±24.9 39.5±41.7 0.001
Ki67 Proliferation Index (%)
Mean ± SD 72 27.8
±12.9
12.2±14 0.0001 25.1±14 12.3
±15.1
0.004 27.8±12.8 13.7±14.7 0.0001
* Both PKM2 and LDH-A positive
** Either PKM2 or LDH-A and both negative
doi:10.1371/journal.pone.0151635.t001
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and Ki-67 (Rabbit polyclonal to Ki-67, Abcam, UK, Cat# ab15580, 1:300), and overnight at 4°C
for PKM2 (Monoclonal mouse anti-human and rat PKM2, ScheBo1Biotech, Giessen, Ger-
many, Cat# S-1, 1:100) and LDHA (LDHA/LDHC (C28H7) Rabbit Monoclonal antibody, Cell
Signaling, UK, Cat #3558, 1:250) in PBS. After three washes with PBS containing 0.5% Tween
20, the sections were incubated with horseradish peroxidase (HRP)–conjugated secondary
antibody for 30 minutes. Primary antibody was detected using the 3, 3’-diaminobenzidine
(DAB) or 3-amino-9-ethyl-carbazole (AEC) detection system kit. The sections were placed in
haematoxylin for 3 minutes, then gently washed and mounted.
Double immunohistochemistry
A double immunostaining kit (PicTure double staining kit, Invitrogen, UK) was used for co-
localisation of PKM2 and CD8 or Ki-67. Briefly, two different enzyme detection systems were
used for the sequential double staining with initial use of the horseradish peroxidase system fol-
lowed by the alkaline phosphate system. Sections were incubated with the anti-PKM2 primary
antibody and HRP secondary antibody, and visualisation was developed with the DAB detec-
tion system. Following this step, sections were washed with PBS, incubated with blocking
serum, followed by primary antibody (anti-CD8 or Ki-67) and Goat anti-Rabbit IgG alkaline
phosphatase secondary antibody. Colour was developed by fast red with counter staining by
haematoxylin.
Evaluation of immunohistochemistry staining
Immunohistochemistry was evaluated using a conference light microscope (AXIO Scope, Carl
Zeiss MicroImaging GmbH, Gottingen, Germany). The assessment of the immunostained
slides was performed independently by two observers, blinded to patient background informa-
tion, and any disparity between the observers was resolved by using a conference microscope.
A comprehensive scoring formula was used for the semi-quantitative evaluation of PKM2
expression as described previously [43], with intensity of staining scored as: 1, weak expression;
2, moderate expression; or 3, strong expression; the extent of staining scored as 1,<33% of
tumour cells positive; 2, 33–67% of tumour cells positive or; 3,>67% of tumour cells positive.
The intensity and extent scores were then multiplied to obtain a single scale of scores of 1, 2, 3,
4, 6, and 9. The scores of 1–3 were defined as weak (or negative) staining, whereas scores 4, 6
and 9 were considered as strong (or positive) staining.
The numbers of CD8+ TILs and Ki-67 positive tumour cells were also counted indepen-
dently by two observers. Initially, the whole slide was scanned at low magnification (x40) to
identify the region with the highest density of intratumoural CD8 or Ki-67-positive tumour
cells and then five random areas within that region were counted at high magnification (x400).
The average number of CD8+ TILs was calculated and expressed as count per high power field
(HPF). The cell proliferation index (PI) was expressed as a percentage of the number of nuclei
stained positive for Ki-67 among 1000 tumour cells using a standardised grid.
Cell cultures
Nine human pancreatic cancer cell lines were purchased from RIKEN BioResource Centre
(RIKEN BRC, Tsukuba, Japan) and the BxPc-3 cell line was purchased from PerknElmer (Cali-
per LifeSciences, Hopkinton, MA, USA). PANC-1, PK-1, PK-59, PK-45H, PK45P, KLM-1,
NOR-P1 and BxPc-3 were maintained in RPMI-1640, Miapaca-2 in DMED and KP-4 in
DMEM/F12 medium. All media were supplemented with 10% fetal bovine serum (FBS), 1%
penicillin/streptomycin and 2mM glutamine (Gibco, Life technologies, UK). Cells were
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maintained in a humidified atmosphere of 21% O2, 5% CO2 at 37°C and harvested with tryp-
sin-EDTA.
Western Blot
PKM2 and LDHA expression was evaluated in pancreatic cancer cell lines by Western Blotting.
Briefly, following protein extraction, protein concentration was measured by the Bicinchoninic
Acid (BCA) assay and 15μg protein was run on a pre-cast gel (NuPAGE Novex 4–12% Bis-Tris
1.0mm, 10 wells gel, Invitrogen, USA) and transferred onto a 0.45μm pore size Polyvinylidene
fluoride (PVDF) membrane (Invitrogen, USA). The membrane was blocked with 5% Bovine
Serum Albumin (BSA) solution and incubated overnight at 4°C either with mouse anti-PKM2
(DF-4, ScheBo1Biotech, Giessen, Germany, 1:1000) or rabbit anti-LDHA antibody (Cell Sig-
naling, UK, 1:1000), and then incubated with appropriate horseradish peroxidase conjugated
secondary antibodies (Cell Signaling, UK, 1:2000). The antigen antibody reaction was detected
by enhanced chemiluminescence substrate (Thermo Scientific, USA). Anti-β actin antibody
(Cell Signaling, UK) was used as a protein loading control.
Statistical analysis
IBM SPSS Statistical software (Version 22, SPSS Inc., Chicago, IL, USA) was used for data anal-
ysis and graphics. Kaplan-Meier plots and log-rank tests were used to analyse survival and to
identify differences between groups. One way ANOVA with Bonferroni post-hoc test was used
for overall comparison of multiple groups, with the Mann-Whitney U-test for nonparametric
tests and the Chi square test for differences between categorical data. Non-parametric correla-
tion analyses between two continuous variables were performed by Spearman test. All test
results were two-tailed, with effects summarised using 95% confidence intervals. Statistical sig-
nificance was set at p<0.05.
Results
Expression of PKM2 and LDHA in pancreatic cancer
Both PKM2 and LDHA were overexpressed in tumour cells compared with normal pancreatic
tissue. A variable expression pattern of PKM2 was observed in tumour tissues, with relatively
higher expression in poorly differentiated areas, in advancing margins of tumour nodules and
in invasive (muscular and blood vessel) tumours (Fig 1A, 1B, 1E and 1F). Overall, PKM2
expression was predominantly associated with aggressive tumours. Preferential expression of
PKM2 was observed in binucleated proliferating cells in tumour nodules (Fig 1D). Expression
of PKM2 was noted in all cell compartments, including the cell membrane, cytoplasm and/or
nucleus (Fig 1C and 1F). In contrast, LDHA expression was generally high in tumour as well as
in preneoplastic tissues and pancreatitis without a specific pattern (Fig 2). LDHA expression
was also detected in the cell membrane and/or cytoplasm and occasionally in the nucleus.
Similar expression of PKM2 and LDHA was observed in the UCLH cohort and TMA sam-
ples, with a staining score of> 3 in 64% and 73% of tumours, respectively, for PKM2, and in
76% of tumours for LDHA in both cohorts. The expression pattern in the pancreatic cancer
cell lines was similar for both PKM2 and LDHA, except in the KP4 cell line in which the
LDHA level was stronger than PKM2 level (Fig 3). In both cohorts, pancreatitis samples also
highly expressed LDHA compared with PKM2 expression (Fig 4).
As shown in Fig 4, progressively higher PKM2 expression was observed along the transition
to pancreatic cancer, with the lowest expression in pancreatic cysts (19%), intermediate in
PanIN (37%) and highest in cancers (68%). PKM2 expression was approximately four-fold
PKM2 and LDHA in Pancreatic Cancer
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higher in pancreatitis (29%) compared with normal pancreatic tissue. Although LDHA expres-
sion was also significantly increased in cancers compared with normal pancreatic tissue
(p< 0.0001, ANOVA), there were no significant differences between chronic pancreatitis, pan-
creatic cysts, PanIN and cancer samples (67%, 59%, 73% and 76%, respectively).
PKM2 and LDHA expression in pancreatic cancer cell lines
ByWestern blotting, high expression of PKM2 and LDHA was detected in 8 and 9 out of the
10 pancreatic cancer cell lines (Fig 3). The expression level of PKM2 and LDHA corresponded
in all cell lines except in the KP4 in which the PKM2 level was weaker than the LDHA level. By
immunohistochemistry, both PKM2 and LDHA had strong cytoplasmic and nuclear expres-
sion (Fig 3).
Fig 1. Immunohistochemical staining of PKM2 expression in representative pancreatic tumour
sections. (A) Well differentiated area of tumour showing weak PKM2 expression (red arrow), with high
expression in poorly differentiated areas (brown colour, yellow arrow) (x100 magnification). (B) Growing
margin of tumour nodules with strong expression of PKM2 (red arrow) (x100 magnification). (C) Membranous
expression of PKM2 (red arrow) (x200 magnification). (D) Heterogeneous expression of PKM2 with
predominant expression in the proliferating cells (red arrow) (x200 magnification). (E) Strongly positive
tumour expression of PKM2 in vascular invasion (red arrow) (x100 magnification). (F) Strongly positive
tumour expression of PKM2 with muscular invasion (red arrow) (x100 magnification).
doi:10.1371/journal.pone.0151635.g001
Fig 2. LDHA expression pattern in pancreatic cancer, benign and normal tissue sections. (A) Membranous expression of LDHA (x200 magnification).
(B) Cytoplasmic and nuclear expression (x200 magnification). (C) Strong expression in pancreatic cyst with mild expression in the surrounding normal
pancreatic tissue (x50 magnification). (D) Nuclear expression of LDHA in pancreatic cancer (x100 magnification). (E) Strong expression in PanIN lesion
(x100 magnification). (F) Negative staining in normal pancreas (x100 magnification).
doi:10.1371/journal.pone.0151635.g002
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Association with clinicopathological parameters
The correlation between PKM2 and LDHA expression with clinicopathological characteristics
is shown in Table 1. There was a significant inverse correlation between PKM2 expression and
tumour differentiation in the UCLH cohort, with 83% of PKM2 positive tumours being less dif-
ferentiated compared with 64% of PKM2 negative tumours (p = 0.047, Chi-square test) (data
not shown).
A significantly higher number of CD8+ TIL was found in tumours with weak PKM2 or
LDHA expression compared with tumours that had a strong expression (p = 0.0001, p = 0.005
respectively, Table 1). Furthermore, a significant association between tumour cell proliferation
and expression of both PKM2 and LDHA was observed; the number of tumour nuclei express-
ing Ki-67 was more than 2-fold higher in PKM2 and LDHA expressing tumours compared
Fig 3. Expression of PKM2 and LDHA in pancreatic cancer cell lines as detected byWestern blot
analysis (upper panel). Immunostaining of Miapaca-2 cells with PKM2 (A) and LDHA (B) is shown in the
lower panel. Strong cytoplasmic and nuclear staining is noted in proliferating cells.
doi:10.1371/journal.pone.0151635.g003
Fig 4. Percentages of PKM2 and LDHA expression in different tissue types. PKM2 was strongly
expressed by pancreatic cancer tissue specimens and was significantly higher than in normal, pancreatitis,
pancreatic cyst and PanIN tissues (P<0.001). Expression of LDHA was significantly higher in pancreatic
cancer than in normal pancreas (P<0.001), whereas, there was no significant differences in LDHA expression
between pancreatic cancer, PanIN, pancreatic cysts and pancreatitis.
doi:10.1371/journal.pone.0151635.g004
PKM2 and LDHA in Pancreatic Cancer
PLOS ONE | DOI:10.1371/journal.pone.0151635 March 18, 2016 8 / 17
with negative tumours (PKM2: 27.8 ± 12.9 vs. 12.2 ± 14, p = 0.0001 and LDHA: 25.1 ± 14 vs.
12.3 ± 15.1, p = 0.004). When staining scores, CD8+ TIL count and the number of Ki-67 posi-
tive cells were considered as continuous variables, a significant inverse correlation between the
staining scores and CD8+ cell count was observed (PKM2: p<0.001 and LDHA: p = 0.004,
Spearman rank correlation). A significant direct correlation was noticed between the staining
scores and Ki-67 count (PKM2: p<0.001 and LDHA: p = 0.001, Spearman rank correlation
test) (Figs 5 and 6). In the TMA cohort, the expression of PKM2 and LDHA correlated with
tumour size. PKM2 expression was observed in 54.5%, 77.8% and 90.9% of tumours that
were 2.5, 2.6–3.9 and 4 cm in size, respectively. Positive LDHA expression was found in
59.1%, 77.8% and 100% in tumours that were 2.5, 2.6–3.9 and 4 cm in size, respectively.
There were no significant differences between PKM2 or LDHA expression and tumour loca-
tion, lymph node involvement, T-stage and metastatic status.
Correlation between PKM2 and LDHA expression and patient survival
We next examined whether expression profile of PKM2 and LDHA predicted survival. Patients
with tumours scoring> 3 for PKM2 or LDHA expression had significantly worse survival
compared with those that weakly expressed PKM2 and/or LDHA. Of the 72 pancreatic cancer
samples (UCLH cohort), 46 (64%) strongly expressed PKM2 and these patients had a median
survival of only 8.9 months compared with 28.9 months in the 26 (36%) patients with weak
(negative) PKM2 tumour expression (p = 0.016, log-rank test, Fig 7). Similarly, 55 (76.4%)
patients with positive LDHA tumour expression had a median survival of 10.9 months com-
pared with 34.5 months of the 17 (23.6%) patients with weak (negative) LDHA tumour expres-
sion (p = 0.029, log-rank test, Fig 7). Moreover, when the expression profile of PKM2 and
LDHA was combined, the survival of patients with negative expression for both or positive for
Fig 5. Immunohistochemical staining and correlation between PKM2 and LDHA and CD8+TIL. (A) Well differentiated tumours with negative PKM2
expression had strong infiltration by CD8+ positive T-lymphocytes (x200 magnification). (B) Poorly differentiated tumours strongly positive for PKM2 had
sparse infiltration by CD8+ positive T-lymphocytes (x200 magnification). There was a significant negative correlation between CD8+ positive cells and both
PKM2 (C) & (D) and LDHA staining (E) & (F).
doi:10.1371/journal.pone.0151635.g005
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one was four times longer than those with a positive status for both (27.9 months vs. 7.0
months, respectively, p = 0.003, log rank test). Among the several survival predictors by the
univariate analysis (T-stage; p = 0.006, tumour differentiation; p = 0.003, metastatic status;
p = 0.000), by Cox regression analysis only the combined PKM2 / LDHA expression status and
tumour differentiation status were independent survival predictors (p = 0.003, Hazard ratio
(HR) = 4.96 and p = 0.015, HR = 3.31, respectively) (Table in S1 Table).
Additionally, 27 of the 72 patients (UCLH cohort) underwent surgical resection for PDAC
(n = 16) or ampullary adenocarcinoma (n = 11). Those who underwent surgical resection had
a significantly longer survival than those who did not undergo surgery (26.5 vs 7.0 months,
P<0.0001; log rank test). As expected, patients with ampullary adenocarcinoma had a better
prognosis after surgery than those with PDAC, with 5 of 11 (45.5%) ampullary carcinoma
patients alive at last contact, compared with only 1 out of 16 (6.3%) patients with PDAC
(P<0.0001; log rank test).
Discussion
There is mounting evidence that cancer cells have elevated glucose uptake with a concomitant
increase in lactate production through sequential catalytic enzyme mediated processes [44,45].
PKM2 and LDHA are two crucial glycolytic enzymes that facilitate these processes to confer
cancer cells with a growth advantage over normal cells. To date, serum PKM2 has been identi-
fied as a diagnostic and prognostic marker with comparable sensitivity and specificity to serum
CA19-9 marker in pancreatic cancer [46–48]. However, there are limited data on the expres-
sion pattern and prognostic impact of PKM2 and LDHA in pancreatic cancer [32,49,50]. To
the best of our knowledge, our study is the first to evaluate the prognostic impact of combined
PKM2 and LDHA expression in the initiation and progression of pancreatic cancer. A recent
study showed overexpression and phosphorylation of both of these enzymes in thyroid cancer
Fig 6. Immunohistochemical staining and correlation between PKM2, LDHA and Ki-67. (A) Tumours with strongly positive PKM2 expression had most
of the nucleus stained for Ki-67 (x100 magnification). (B) Tumours weakly positive for PKM2 had scant Ki67 staining (x100 magnification). (C) & (D)
Correlation between PKM2 staining and Ki-67 positive cells. (E) & (F) Correlation between LDHA staining and Ki-67 positive cells. There was a significant
correlation for both PKM2 and LDHA.
doi:10.1371/journal.pone.0151635.g006
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compared with benign goitre [51]. Our results concur with their findings showing significant
overexpression of PKM2 and LDHA in pancreatic cancers compared with normal pancreatic
tissue.
Fig 7. Overall patient survival in relation to PKM2 and LDHA expression. Both PKM2 (A) and LDHA (B) had a significant prognostic impact on patient
survival (p = 0.016, 0.029, log rank test, respectively) and the combined expression for both markers further stratified the patients (C) (p = 0.003, log rank
test). As expected, patients who underwent surgical resection had a longer survival than unresected patients.
doi:10.1371/journal.pone.0151635.g007
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The step-wise initiation and development of pancreatic cancer often begins with pancreati-
tis, ductal metaplasia, cyst formation or PanIN lesions, leading to pancreatic cancer. Interest-
ingly, our results demonstrate overexpression of LDHA at a very early stage along the
carcinogenetic pathway from pancreatitis through cyst/PanIN to cancer with the highest
expression in the most aggressive tumours. In contrast, PKM2 expression increased progres-
sively along the transition to pancreatic cancer and was lowest in cysts, intermediate in PanIN
lesions and highest in cancers. Although the exact mechanism of this differential expression
pattern remains to be elucidated, it is possible that the pre-neoplastic lesions acquire the glyco-
lytic phenotype through LDHA overexpression and then LDHA itself or other oncogenes
induce PKM2 overexpression at later stages when tumour cell proliferation rates are higher. In
fact, it has been recently shown that the epidermal growth factor receptor (EGFR) induces β-
catenin transactivation and c-myc expression, upregulating LDHA, which in turn induces
upregulation of PKM2 expression by alternating splicing of the gene fromM1 to M2 type [52].
These findings might partially explain the consistent overexpression of LDHA throughout the
tumorigenic process and the progressive overexpression of PKM2 along the carcinogenetic
pathway. The expression and enzymatic activity of LDHA and PKM2 can also be modulated
by tyrosine phosphorylation at various residues (Y10 and Y105, respectively) by the oncogenic
tyrosine kinase fibroblast growth factor receptor-1 [53]. The differential expression pattern
suggests that PKM2 (or a combination of PKM2 and LDHA) would be a better choice for dis-
criminating cancer from pre-neoplastic lesions compared with LDHA alone, except in pancrea-
titis where both markers are highly expressed.
Treating pancreatic cancer is highly challenging due to late diagnosis, and lack of appropri-
ate prognostic markers and effective therapies. Our results demonstrate that both PKM2 or
LDHA are significant prognostic markers in pancreatic cancer and the combination provides
improved stratification of outcome. These results are in line with previous publications show-
ing a significant prognostic effect of LDHA or PKM2 in other tumour types, including squa-
mous cell carcinoma, cholangiocarcinoma and gastric cancer [43,54,55]. The exact
mechanisms associated with the overexpression of PKM2 and LDHA that lead to poor progno-
sis remain unclear. Very recently, Rajeshkumar et al (2015) found that the LDHA small mole-
cule inhibitor FX11 can impede tumour growth, reduce tumour cell proliferation and induce
apoptosis in a patient-derived mouse xenograft model of pancreatic cancer with mutant TP53,
while tumours harbouring wild-type TP53 were completely resistant to FX11 [56].
Pancreatic cancer is one of the more aggressive tumour types, with a very poor overall sur-
vival. The results of our study clearly show up-regulation of both PKM2 and LDHA in pancre-
atic cancer and implicate the high expression of these two glycolytic enzymes in the
development and progression of pancreatic cancer through enhanced proliferation, migration,
invasion and angiogenesis. Feng et al (2014) reported that the knockdown of PKM2 in pancre-
atic cancer cells reduces cell proliferation, migration and invasion of pancreatic cancer cells in
vitro and induces apoptosis by increasing the expression level of BAX protein and reducing the
expression level of Bcl-2 protein [57]. In a related study, Azoitei et al (2013) demonstrated that
the knockdown of PKM2 by siRNA attenuates pancreatic cancer cell proliferation and migra-
tion in vitro and impedes tumour growth, angiogenesis and Ki67 expression in the pancreatic
cancer xenograft model [58].
In this study, we noticed a significant direct correlation between staining scores and the
tumour cell proliferation index, and by using the double labeling technique, we were able to
identify Ki-67 positive proliferating cells topographically co-localising in PKM2 positive areas.
It has been well recognized that these glycolytic enzymes translocate to the nucleus and interact
with several other oncogenic transcription factors and transcribe several cell proliferating sig-
naling pathways including Stat3, β-catenin, HIF-1, Oct-4, cyclin D1 [42]. Moreover, PKM2 has
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been implicated in the phosphorylation of the chromosomal spindle checkpoint protein Bub3--
Bub1-Blinkin complex, which ensures fidelity of chromosomal segregation during cell prolifer-
ation [59]. Although we could not find any significant correlation with tumour stage and
metastasis status, strong expression of PKM2 was observed in metastatic tumours invading
muscle and blood vessels, indicating the aggressive phenotype of pancreatic tumours express-
ing the glycolytic enzymes. We and others have previously shown in cholangiocarcinoma and
lung cancer, respectively, that tumour-associated angiogenesis is induced by PKM2 and
LDHA, which could be another contributing factor to poor prognosis [43,60].
Host immune evasion is a hallmark of the aggressive tumour phenotype. Although a limited
number of studies have provided evidence of mechanism between host immune suppression
and the tumour glycolytic phenotype, to date, there is no concrete evidence showing a correla-
tion between the expression of PKM2, LDHA and CD8+ effector cell infiltration. Interestingly,
we noticed a significant inverse correlation between the PKM2 and LDHA expression and
CD8+ cell infiltration, with an accumulation of CD8+ cells in tumours that did not express
PKM2. Recently, Crane et al (2014) reported that LDHA secreted by glioblastoma cells down-
regulated the Natural Killer group 2, member D receptor on natural killer cells and thus sub-
verted host immune surveillance [61]. Similarly, Liu et al (2015) reported that PKM2
expression was related to increased infiltration of primary and metastatic tumours by myeloid
derived suppressor cells, responsible for the suppression of NK cells and induction of host
immune suppression by regulatory T cells [62]. We postulate that the compromised immune
surveillance induced by enhanced expression of PKM2 and LDHA, and reduced CD8+ effector
T-cells might be another contributing factor associated with poor prognosis of the glycolytic
phenotype of pancreatic cancer.
Limitations of our study include limited sample size and lack of some clinicopathological
information. An optimal scoring system for PKM2 and LDHA expression has not yet been
established, with various scoring systems having been reported [43,63–66]. In the current
study, PKM2 and LDHA expression scores were classified as negative or positive, which was
based on the intensity and extent of PKM2 and LDHA expression across tumour areas. More-
over, other treatments such as chemotherapy might have affected the levels of PKM2 and
LDHA expression and overall survival of patients.
In conclusion, we have shown a differential expression pattern for PKM2 and LDHA from
cysts through PanIN lesions to pancreatic cancer, with upregulation of LDHA throughout the
carcinogenetic process and a progressive upregulation of PKM2 expression along the carcino-
genetic pathway. Moreover, the combined expression of these glycolytic enzymes is a strong
independent marker of poor prognosis, attributable to increased cell proliferation, larger
tumour size and host immune evasion. Further studies are underway to evaluate these markers
as possible targets for therapy in pre-clinical models of pancreatic cancer.
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